Ovarian cancer ranks among the most lethal gynecological cancers, largely because it is often detected at advanced stages and recurs frequently despite initial response to surgery and chemotherapy. Most cases are epithelial, with High-grade Serous Ovarian Cancer (HGSOC) being the most common and aggressive, typically diagnosed at advanced stages. Targeted therapies are reshaping treatment toward precision and personalization.
For over three decades, the cornerstone of ovarian cancer treatment has been surgery combined with platinum-based chemotherapy, typically a platinum analog like cisplatin or carboplatin paired with a taxane such as paclitaxel or docetaxe...
